Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Axogen, Inc. Director's Dealing 2014

May 12, 2014

32414_dirs_2014-05-12_f7f1b4ce-6f10-4968-9a65-71bdd0a729ae.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2013-01-01

Reporting Person: Mandato Joseph M (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-05-05 Common Stock A 15000 $2.64 Acquired 30000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-01-01 Stock Option (Right to Buy) $2.75 A 13000 Acquired 2020-01-01 Common Stock (13000) Direct
2014-01-02 Stock Option (Right to Buy) $4.81 A 15000 Acquired 2014-01-02 Common Stock (15000) Direct

Footnotes

F1: Price reflected is the weighted-average purchase price for shares purchased. The range of purchase prices for the transactions reported was $2.62 to $2.65 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F2: Annual option grant as compensation for service on the board of directors. All options vested on the date of grant.

F3: Annual option grant as compensation for service on the board of directors. Options vest as to 25% of total shares at the end of each fiscal quarter, becoming fully vested after one year.